What's Happening?
hVIVO PLC has signed a consultancy contract with Decoy Therapeutics to support the development of a new class of broad-spectrum respiratory antivirals. The collaboration will focus on translational modeling, regulatory strategy, and preparation of clinical
documentation for European and UK regulators. Decoy is developing Designable Multi-Antiviral (D-MAV) candidates, which target shared mechanisms across multiple respiratory viruses. The consultancy aims to support first-in-human dose selection and pharmacology planning, with plans to progress to Phase I studies.
Why It's Important?
This partnership highlights the growing need for innovative antiviral therapies that can address multiple respiratory viruses with a single treatment. The collaboration leverages hVIVO's expertise in human challenge trials and regulatory services, potentially accelerating the development of Decoy's D-MAV candidates. Successful development of these antivirals could provide a significant tool in managing respiratory virus outbreaks, reducing the burden on healthcare systems and improving patient outcomes.
What's Next?
Decoy Therapeutics plans to advance its D-MAV candidates to Phase I and proof-of-concept studies, contingent on securing additional funding. The collaboration with hVIVO will continue to focus on regulatory submissions and clinical trial planning. The success of this partnership could lead to further collaborations and advancements in antiviral drug development.
